BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
TEL AVIV, Israel, Sept. 14, 2017 -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference. The conference will be held September 25-27, 2017 at the InterContinental New York Barclay Hotel, New York City.
Presentation Details:
Date: Tuesday, September 26, 2017
Time: 9:45-10:15 AM Eastern Time
Location: Grand Ballroom 2; InterContinental New York Barclay Hotel
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class biologic agent that uses a dual mechanism to target solid tumors. It utilizes an angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter) to specifically target the tumor vasculature, by induction of cell death in angiogenic endothelial cells in the tumor milieu. Moreover, it is an immune-stimulant that triggers a local anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec is positioned to treat a wide range of solid tumors and is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC [email protected] (646) 597-6979 MEDIA CONTACT: Matt Middleman, M.D. LifeSci Public Relations [email protected] (646) 627-8384
